Last 11 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -41.70 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4041.01 | 463.79 | — | 8970.36 | 1019.21 | 14728.68 | 4739.02 | 1382.62 | — | — | — | — |
| — | -96.9% | — | +548.8% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.01 | 4.49 | 2.96 | 2.65 | 2.53 | 4.72 | 3.81 | 5.14 | — | — | — | — |
| — | -4.8% | -22.4% | -48.5% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CG Oncology, Inc. Common stock's operating margin was -3069.0% in Q3 2025, up 62733.4 pp YoY. The trailing four-quarter average of -30858.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 94.7% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 5.3% | — | 100.0% | 100.0% | 100.0% | 100.0% | 99.2% | -300.0% | -130288.9% | -3942.3% | — |
| — | -94.7% | — | +0.8% | +133.3% | +100.1% | +102.5% | — | — | — | — | — | |
| Operating Margin | -10067.3% | -3069.0% | — | -81161.5% | -8344.1% | -65802.3% | -23291.0% | -4247.4% | -1893200.0% | -156033.3% | -5010.8% | — |
| — | +95.3% | — | -1810.8% | +99.6% | +57.8% | -364.8% | — | — | — | — | — | |
| Net Margin | -7729.5% | -2629.5% | — | -66253.8% | -6973.2% | -47453.5% | -17028.8% | -3200.8% | -1611600.0% | -130755.6% | -4467.5% | — |
| — | +94.5% | — | -1969.9% | +99.6% | +63.7% | -281.2% | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -19.2% | -6.5% | -6.0% | -4.8% | -5.0% | -3.7% | -3.4% | -4.5% | -8.4% | -7.2% | -6.9% | -6.7% |
| — | -72.2% | -78.7% | -6.6% | +40.2% | +48.3% | +51.3% | +33.0% | — | — | — | — | |
| ROA | -18.5% | -6.1% | -5.8% | -4.6% | -4.9% | -3.7% | -3.3% | -4.4% | -7.8% | -5.6% | — | -5.7% |
| — | -67.5% | -75.3% | -6.8% | +37.9% | +34.2% | — | +23.4% | — | — | — | — | |
| ROIC | -26.3% | -5.9% | -5.5% | -5.5% | -5.9% | -4.2% | -3.8% | -5.0% | -7.7% | -4.6% | -4.5% | — |
| — | -41.2% | -45.5% | -10.2% | +23.8% | +9.5% | +16.1% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 35.5% YoY to 22.79x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | — | 0.13 |
| — | +1811.1% | +130.6% | +107.0% | -94.2% | -78.7% | — | -99.4% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 35.30 | 22.79 | 22.15 | 30.97 | 35.30 | 35.32 | 47.57 | 57.95 | 13.62 | 17.92 | — | 9.54 |
| — | -35.5% | -53.4% | -46.6% | +159.2% | +97.1% | — | +507.4% | — | — | — | — | |
| Quick Ratio | 35.30 | 22.74 | 22.15 | 30.97 | 35.30 | 35.32 | 47.57 | 57.95 | 13.62 | 17.92 | — | 9.54 |
| — | -35.6% | -53.4% | -46.6% | +159.2% | +97.1% | — | +507.4% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 11 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCG Oncology, Inc. Common stock's current P/E is -41.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CG Oncology, Inc. Common stock's current operating margin is -10067.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CG Oncology, Inc. Common stock's business trajectory between earnings reports.